Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
KalVista Pharmaceuticals, Inc is a biotechnology business based in the US. KalVista Pharmaceuticals shares (KALV) are listed on the NASDAQ and all prices are listed in US Dollars. KalVista Pharmaceuticals employs 70 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$27.00|
|52-week range||$9.69 - $43.08|
|50-day moving average||$24.30|
|200-day moving average||$25.94|
|Wall St. target price||$55.43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.38|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-25)||N/A|
|1 month (2021-07-02)||15.19%|
|3 months (2021-05-05)||8.26%|
|6 months (2021-02-01)||N/A|
|1 year (2020-08-01)||N/A|
|2 years (2019-08-01)||N/A|
|3 years (2018-08-01)||N/A|
|5 years (2016-08-01)||N/A|
|Revenue TTM||$3.8 million|
|Gross profit TTM||$-41,286,000|
|Return on assets TTM||-19.86%|
|Return on equity TTM||-27.13%|
|Market capitalisation||$504.7 million|
TTM: trailing 12 months
There are currently 2.0 million KalVista Pharmaceuticals shares held short by investors – that's known as KalVista Pharmaceuticals's "short interest". This figure is 1.8% down from 2.0 million last month.
There are a few different ways that this level of interest in shorting KalVista Pharmaceuticals shares can be evaluated.
KalVista Pharmaceuticals's "short interest ratio" (SIR) is the quantity of KalVista Pharmaceuticals shares currently shorted divided by the average quantity of KalVista Pharmaceuticals shares traded daily (recently around 330449.07251265). KalVista Pharmaceuticals's SIR currently stands at 5.93. In other words for every 100,000 KalVista Pharmaceuticals shares traded daily on the market, roughly 5930 shares are currently held short.
However KalVista Pharmaceuticals's short interest can also be evaluated against the total number of KalVista Pharmaceuticals shares, or, against the total number of tradable KalVista Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case KalVista Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 KalVista Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.1087% of the tradable shares (for every 100,000 tradable KalVista Pharmaceuticals shares, roughly 109 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against KalVista Pharmaceuticals.
Find out more about how you can short KalVista Pharmaceuticals stock.
We're not expecting KalVista Pharmaceuticals to pay a dividend over the next 12 months.
KalVista Pharmaceuticals's shares were split on a 1:14 basis on 21 November 2016. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your KalVista Pharmaceuticals shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for KalVista Pharmaceuticals shares which in turn could have impacted KalVista Pharmaceuticals's share price.
Over the last 12 months, KalVista Pharmaceuticals's shares have ranged in value from as little as $9.6905 up to $43.0799. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while KalVista Pharmaceuticals's is 1.9954. This would suggest that KalVista Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts. .
Everything we know about the Chobani IPO, plus information on how to buy in.
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.